Liver-Chip: Reproducing Human and Cross-Species Toxicities

Jang, K.-J.; Otieno, M.; Ronxhi, J.; Lim, H.-K.; Ewart, L.; Kodella, K.; Petropolis, D.; Kulkarni, G.; Rubins, J.; Conegliano, D.; Nawroth, J.; Simic, D.; Lam, W.; Singer, M.; Barale, E.; Singh, B.; Sonee, M.; Streeter, A.; Manthey, C.; Jones, B.; Srivastava, A.; Andersson, L.; Williams, D.; Park, H.; Barrile, R.; Sliz, J.; Herland, A.; Haney, S.; Karalis, K.; Ingber, D.; Hamilton, G.

doi:10.1101/631002

Home/Archive/bioRxiv

bioRxiv · 10.1101/631002

Liver-Chip: Reproducing Human and Cross-Species Toxicities

View original source ↗Export metadata ↓

Abstract

Nonclinical rodent and non-rodent toxicity models used to support clinical trials of candidate drugs may produce discordant results or fail to predict complications in humans contributing to drug failures in the clinic. Here we applied microengineered Organ-on-Chip (Organ-Chip) technology to design rat, dog, and human Liver-Chips containing species-specific primary hepatocytes interfaced with liver sinusoidal endothelial cells, with or without Kupffer cells and hepatic stellate cells, cultured under physiological fluid flow. The Liver-Chips detected diverse phenotypes of liver toxicity including hepatocellular injury, steatosis, cholestasis, and fibrosis as well as species-specific toxicities when treated with tool compounds. Multi-species Liver-Chips may provide a useful platform for prediction of liver toxicity and inform human relevance of liver toxicities detected in animal studies to better determine safety and human risk.\n\nOne Sentence SummaryMicroengineered Organ-Chip technology has been used to design rat, dog and human Liver-Chips that recapitulate species-specific liver toxicities.

Explore related subjects

pharmacology and toxicology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Jang, K.-J., Otieno, M., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K., Petropolis, D., Kulkarni, G., Rubins, J., Conegliano, D., Nawroth, J., Simic, D., Lam, W., Singer, M., Barale, E., Singh, B., Sonee, M., Streeter, A., Manthey, C., Jones, B., Srivastava, A., Andersson, L., Williams, D., Park, H., Barrile, R., Sliz, J., Herland, A., Haney, S., Karalis, K., Ingber, D., Hamilton, G.. 2019-05-15. Liver-Chip: Reproducing Human and Cross-Species Toxicities. https://doi.org/10.1101/631002

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

The collective effect of non-nicotine constituents on the reinforcing and neuropharmacological effects of comprehensive cigarette smoke and electronic nicotine delivery system (ENDS) aerosol extracts in rats.

Tobacco product extracts containing nicotine and non-nicotine constituents are useful for understanding the collective role of these constituents in tobacco use disorder (TUD). However, few studies have used extracts with both water-soluble and non-water-soluble constituents with accompanying chemical analysis, or compared behavioral and neuropharmacological effects across product types. To address these limitations, we compared the relative abuse liability of cigarette smoke (CS) and electronic nicotine delivery system (ENDS) aerosol (EA) extracts to nicotine alone using intravenous self-administration in rats, and examined effects on nucleus accumbens (NAc) dopamine (DA) release and binding/function at nicotinic acetylcholine receptors (nAChRs) and other addiction-related receptors in vitro. CS extract contained higher levels of several behaviorally active non-nicotine constituents than EA extract. Both extracts produced a downward/leftward shift in the descending limb of the unit dose-response curve relative to nicotine alone, while only CS extract produced greater compensatory increases in responding compared to nicotine alone. Demand intensity (Q0) was lower for CS but not EA extract, relative to nicotine alone, whereas demand elasticity for both extracts was similar to nicotine alone. Stress-induced reinstatement was comparable between CS extract and nicotine alone but attenuated for EA extract. CS extract, but not EA extract, showed greater potency for 4{beta}2 nAChR activation and substantial binding across numerous non-nAChRs (DA, serotonergic, opioid) relative to nicotine alone at a high screening concentration. CS extract, but not nicotine alone, also inhibited cyclooxygenase (COX)-1 and -2 at smoking-relevant concentrations. There was no difference in NAc DA release between formulations. These findings indicate non-nicotine constituents contribute to certain reinforcing and neuropharmacological effects of CS, and to a lesser extent EA. Our finding of COX inhibition by CS extract warrants further investigation as a potential mechanism contributing to the effects of CS and TUD.

pharmacology and toxicology↗

bioRxiv2026

Fragment Covalent Bond Formation at SOS1 Tyr-884 Inhibits KRAS Nucleotide Exchange

The activation of the KRAS oncogene from its inactive GDP-bound state to its active GTP-bound state is mediated by Son of Sevenless (SOS) exchange factors. Small-molecule inhibition of SOS1 has been achieved, with three compounds currently in clinical trials. These compounds bind to SOS1 and disrupt a crucial interaction between SOS1 Tyr-884 and KRAS Arg-73. Here, we screen libraries of aryl sulfonyl fluorides to explore covalent bond formation at Tyr-884 as a strategy for covalent inhibition of SOS1-KRAS binding. Initially, ten fragments were tested and several inhibited KRAS nucleotide exchange by SOS1. X-ray crystal structures revealed that one reaction site for the fragments was Tyr-884, but mass spectrometry and nucleotide exchange assays with wild-type and mutant SOS1 indicated additional reaction sites. To identify candidates specific to Tyr-884, we conducted a larger screen and identified fragment 11 (SOF-599). The fragment formed an adduct predominantly at Tyr-884 and inhibited KRAS nucleotide exchange by SOS1 in a time- and concentration-dependent manner. Fragment 11 (SOF-599) exhibited a half-maximal inactivation concentration (KI) of 12 micromolar and a reaction half-life of 6 h. These findings establish 11 (SOF-599) as a promising starting point for the development of covalent SOS1 inhibitors as an alternative strategy to existing non-covalent antagonists.

pharmacology and toxicology↗

bioRxiv2026

Complementary chemical and effect-based risk assessments reveal ecotoxicological risks in Caribbean coastal bays and coral reefs

Anthropogenic chemical pollution poses a significant, yet often unquantified threat to coral reef ecosystems. This study investigated the occurrence, dispersal, and ecotoxicological risks of chemical mixtures in three inland bays of Curacao (Southern Caribbean) and adjacent coral reefs during wet and dry seasons. Passive sampler extracts were analyzed with targeted chemical analysis and effect-based methods. Inland bays acted as reservoirs for chemical pollution, each exhibiting a unique chemical fingerprint likely linked to surrounding land use. Targeted chemical concentrations were higher during the wet season, particularly inside the bays, indicating rainfall-driven mobilization of terrestrial contaminants. Many compounds exceeded their predicted no-effect concentrations, while mixture toxic pressure was low to moderate and highest inside the bays. In contrast, bioassays integrating the effects of the entire mixture revealed a potential ecotoxicological risk, with activation of the Nrf2 oxidative stress pathway dominating across reef sites. The two lines of evidence were complementary: target compounds identify the bays as pollution sources, while bioassays show mixture effects are strongest on the reefs. Hence,targeted chemical analysis alone is insufficient to evaluate ecotoxicological risk. Our multidisciplinary approach provides a framework for prioritizing key chemical indicators and bioassays to monitor coral reef water quality.

pharmacology and toxicology↗